Cancer risk in dermatomyositis: A systematic review of the literature

D. Di Rollo, D. Abeni, M. Tracanna, A. Capo, P. Amerio

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The association between idiopathic inflammatory myopathy (IIM) and cancer has been extensively studied in adults. Many epidemiological studies demonstrated this association, which appears stronger for dermatomyositis (DM) than for polymyositis (PM). The first case suggesting an association between cancer and DM was reported in 1916. At present the reported incidence of cancer association with DM varies widely, from less than 7% to over 30%. Many early evidences came from case reports, but this association was later confirmed in case-control as well as in population-based studies. Ovarian cancer or breast cancer in females and lung cancer in males are the main malignancies associated with DM. Given the frequency of the association of dermatomyositis with cancer, for cost-effectiveness reasons it might be important to develop simple and appropriate diagnostic tests for identification of patients with DM, who may be at higher risk of developing a malignancy. Clinicians should plan follow-up schedules to optimize both cancer detection and treatment, and thus to improve patient survival. Many different clinical and serological signs have been suggested as possible predictive factors for malignancy in dermatomyositis: age, increased erythrocyte sedimentation rate (ESR), presence of cutaneous leukocytoclastic vasculitis, cutaneous rash and skin lesions as cutaneous necrosis and periungueal erythemas, neoplastic markers or dysphagia. The results of the different studies are quite discordant. Therefore, we conducted a systematic review of the scientific literature to evaluate the level of the risk of cancer in patients with dermatomyositis and to explore whether certain patient characteristics may be linked to different levels of cancer risk.

Original languageEnglish
Pages (from-to)525-537
Number of pages13
JournalGiornale Italiano di Dermatologia e Venereologia
Volume149
Issue number5
Publication statusPublished - Oct 1 2014

Fingerprint

Dermatomyositis
Neoplasms
Cutaneous Leukocytoclastic Vasculitis
Breast Neoplasms
Skin
Myositis
Blood Sedimentation
Erythema
Deglutition Disorders
Exanthema
Routine Diagnostic Tests
Ovarian Neoplasms
Cost-Benefit Analysis
Epidemiologic Studies
Lung Neoplasms
Appointments and Schedules
Necrosis

Keywords

  • Dermatomyositis
  • Neoplasms
  • Skin diseases

ASJC Scopus subject areas

  • Dermatology
  • Medicine(all)

Cite this

Cancer risk in dermatomyositis : A systematic review of the literature. / Di Rollo, D.; Abeni, D.; Tracanna, M.; Capo, A.; Amerio, P.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 149, No. 5, 01.10.2014, p. 525-537.

Research output: Contribution to journalArticle

Di Rollo, D, Abeni, D, Tracanna, M, Capo, A & Amerio, P 2014, 'Cancer risk in dermatomyositis: A systematic review of the literature', Giornale Italiano di Dermatologia e Venereologia, vol. 149, no. 5, pp. 525-537.
Di Rollo, D. ; Abeni, D. ; Tracanna, M. ; Capo, A. ; Amerio, P. / Cancer risk in dermatomyositis : A systematic review of the literature. In: Giornale Italiano di Dermatologia e Venereologia. 2014 ; Vol. 149, No. 5. pp. 525-537.
@article{cc51d743db024ed58fed5c8273ef0b06,
title = "Cancer risk in dermatomyositis: A systematic review of the literature",
abstract = "The association between idiopathic inflammatory myopathy (IIM) and cancer has been extensively studied in adults. Many epidemiological studies demonstrated this association, which appears stronger for dermatomyositis (DM) than for polymyositis (PM). The first case suggesting an association between cancer and DM was reported in 1916. At present the reported incidence of cancer association with DM varies widely, from less than 7{\%} to over 30{\%}. Many early evidences came from case reports, but this association was later confirmed in case-control as well as in population-based studies. Ovarian cancer or breast cancer in females and lung cancer in males are the main malignancies associated with DM. Given the frequency of the association of dermatomyositis with cancer, for cost-effectiveness reasons it might be important to develop simple and appropriate diagnostic tests for identification of patients with DM, who may be at higher risk of developing a malignancy. Clinicians should plan follow-up schedules to optimize both cancer detection and treatment, and thus to improve patient survival. Many different clinical and serological signs have been suggested as possible predictive factors for malignancy in dermatomyositis: age, increased erythrocyte sedimentation rate (ESR), presence of cutaneous leukocytoclastic vasculitis, cutaneous rash and skin lesions as cutaneous necrosis and periungueal erythemas, neoplastic markers or dysphagia. The results of the different studies are quite discordant. Therefore, we conducted a systematic review of the scientific literature to evaluate the level of the risk of cancer in patients with dermatomyositis and to explore whether certain patient characteristics may be linked to different levels of cancer risk.",
keywords = "Dermatomyositis, Neoplasms, Skin diseases",
author = "{Di Rollo}, D. and D. Abeni and M. Tracanna and A. Capo and P. Amerio",
year = "2014",
month = "10",
day = "1",
language = "English",
volume = "149",
pages = "525--537",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "5",

}

TY - JOUR

T1 - Cancer risk in dermatomyositis

T2 - A systematic review of the literature

AU - Di Rollo, D.

AU - Abeni, D.

AU - Tracanna, M.

AU - Capo, A.

AU - Amerio, P.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - The association between idiopathic inflammatory myopathy (IIM) and cancer has been extensively studied in adults. Many epidemiological studies demonstrated this association, which appears stronger for dermatomyositis (DM) than for polymyositis (PM). The first case suggesting an association between cancer and DM was reported in 1916. At present the reported incidence of cancer association with DM varies widely, from less than 7% to over 30%. Many early evidences came from case reports, but this association was later confirmed in case-control as well as in population-based studies. Ovarian cancer or breast cancer in females and lung cancer in males are the main malignancies associated with DM. Given the frequency of the association of dermatomyositis with cancer, for cost-effectiveness reasons it might be important to develop simple and appropriate diagnostic tests for identification of patients with DM, who may be at higher risk of developing a malignancy. Clinicians should plan follow-up schedules to optimize both cancer detection and treatment, and thus to improve patient survival. Many different clinical and serological signs have been suggested as possible predictive factors for malignancy in dermatomyositis: age, increased erythrocyte sedimentation rate (ESR), presence of cutaneous leukocytoclastic vasculitis, cutaneous rash and skin lesions as cutaneous necrosis and periungueal erythemas, neoplastic markers or dysphagia. The results of the different studies are quite discordant. Therefore, we conducted a systematic review of the scientific literature to evaluate the level of the risk of cancer in patients with dermatomyositis and to explore whether certain patient characteristics may be linked to different levels of cancer risk.

AB - The association between idiopathic inflammatory myopathy (IIM) and cancer has been extensively studied in adults. Many epidemiological studies demonstrated this association, which appears stronger for dermatomyositis (DM) than for polymyositis (PM). The first case suggesting an association between cancer and DM was reported in 1916. At present the reported incidence of cancer association with DM varies widely, from less than 7% to over 30%. Many early evidences came from case reports, but this association was later confirmed in case-control as well as in population-based studies. Ovarian cancer or breast cancer in females and lung cancer in males are the main malignancies associated with DM. Given the frequency of the association of dermatomyositis with cancer, for cost-effectiveness reasons it might be important to develop simple and appropriate diagnostic tests for identification of patients with DM, who may be at higher risk of developing a malignancy. Clinicians should plan follow-up schedules to optimize both cancer detection and treatment, and thus to improve patient survival. Many different clinical and serological signs have been suggested as possible predictive factors for malignancy in dermatomyositis: age, increased erythrocyte sedimentation rate (ESR), presence of cutaneous leukocytoclastic vasculitis, cutaneous rash and skin lesions as cutaneous necrosis and periungueal erythemas, neoplastic markers or dysphagia. The results of the different studies are quite discordant. Therefore, we conducted a systematic review of the scientific literature to evaluate the level of the risk of cancer in patients with dermatomyositis and to explore whether certain patient characteristics may be linked to different levels of cancer risk.

KW - Dermatomyositis

KW - Neoplasms

KW - Skin diseases

UR - http://www.scopus.com/inward/record.url?scp=84925552512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925552512&partnerID=8YFLogxK

M3 - Article

C2 - 24975953

AN - SCOPUS:84925552512

VL - 149

SP - 525

EP - 537

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 5

ER -